Today Tricida $TCDA announced an “administrative stop” for its VALOR-CKD trial after watching 237 patients reach a primary endpoint event — renal death, end-stage renal disease, or greater than or equal to 40% reduction in estimated glomerular filtration rate — in the renal outcomes study for their metabolic acidosis and CKD drug veverimer. They’ll continue to track events into Q3 as they look for a top-line readout in the near term.